-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 14, Fosun Pharma announced that the cycloserine capsules independently developed by its holding subsidiary, Hongqi Pharma, have been successfully used in the treatment of active pulmonary tuberculosis and extrapulmonary tuberculosis (including renal tuberculosis) for which first-line anti-tuberculosis drugs are not effective.
As of the date of this announcement, the cycloserine capsules approved for listing in China (excluding Hong Kong, Macao and Taiwan, the same below) mainly include Celexin® from Zhejiang Hisun Pharmaceutical Co.
As of January 2022, the Group has invested approximately RMB 10.